Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors

Overview

Journal Future Virol

Specialty Microbiology

Date 2011 Jul 9

PMID 21738557

Citations 45

Authors

Seth M Gregory

Shoab A Nazir

Jordan P Metcalf

Affiliations

Soon will be listed here.

Abstract

Adenovirus (AdV) is a common cause of respiratory illness in both children and adults. Respiratory symptoms can range from those of the common cold to severe pneumonia. Infection can also cause significant disease in the immunocompromised and among immunocompetent subjects in close quarters. Fortunately, infection with AdV in the normal host is generally mild. This is one reason why its initial use as a gene-therapy vector appeared to be so promising. Unfortunately, both innate and adaptive responses to the virus have limited the development of AdV vectors as a tool of gene therapy by increasing toxicity and limiting duration of transgene expression. This article will focus on the innate immune response to infection with wild-type AdV and exposure to AdV gene-therapy vectors. As much of the known information relates to the pulmonary inflammatory response, this organ system will be emphasized. This article will also discuss how that understanding has led to the creation of new vectors for use in gene therapy.

Citing Articles

Immunological pathogenesis and treatment progress of adenovirus pneumonia in children.

Liang Y, Wei J, Shen J, Liang Z, Ma X, Du Y Ital J Pediatr. 2025; 51(1):4.

PMID: 39789604 PMC: 11715079. DOI: 10.1186/s13052-024-01836-1.

Ocular Gene Therapy: An Overview of Viral Vectors, Immune Responses, and Future Directions.

Banou L, Sarrafpour S, Teng C, Liu J Yale J Biol Med. 2024; 97(4):491-503.

PMID: 39703610 PMC: 11650918. DOI: 10.59249/HWID7537.

Therapeutic Gene Editing in Dyslipidemias.

Tamehri Zadeh S, Shapiro M Rev Cardiovasc Med. 2024; 25(8):286.

PMID: 39228490 PMC: 11367006. DOI: 10.31083/j.rcm2508286.

What's New in Ocular Drug Delivery: Advances in Suprachoroidal Injection since 2023.

Wu K, Gao A, Giunta M, Tran S Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204112 PMC: 11357265. DOI: 10.3390/ph17081007.

COVID-19 Variants and Vaccine Development.

Zhao Z, Bashiri S, Ziora Z, Toth I, Skwarczynski M Viruses. 2024; 16(5).

PMID: 38793638 PMC: 11125726. DOI: 10.3390/v16050757.

References

McCoy R, Davidson B, Roessler B, Huffnagle G, Janich S, Laing T . Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther. 1995; 6(12):1553-60. DOI: 10.1089/hum.1995.6.12-1553. View

BELADI I, Pusztai R . Interferon-like substance produced in chick fibroblast cells inoculated with human adenoviruses. Z Naturforsch B. 1967; 22(2):165-9. DOI: 10.1515/znb-1967-0211. View

Nijsten M, de Groot E, Ten Duis H, Klasen H, Hack C, Aarden L . Serum levels of interleukin-6 and acute phase responses. Lancet. 1987; 2(8564):921. DOI: 10.1016/s0140-6736(87)91413-9. View

. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Hum Gene Ther. 2002; 13(1):3-13. DOI: 10.1089/10430340152712629. View

Shirley P, Andrews J, Tinlin S, Webster S, Cameron C, Hough C . Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood. 2001; 97(1):107-13. DOI: 10.1182/blood.v97.1.107. View

Levine A, Whitsett J, Hartshorn K, Crouch E, Korfhagen T . Surfactant protein D enhances clearance of influenza A virus from the lung in vivo. J Immunol. 2001; 167(10):5868-73. DOI: 10.4049/jimmunol.167.10.5868. View

Schagen F, Ossevoort M, Toes R, Hoeben R . Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol. 2004; 50(1):51-70. DOI: 10.1016/S1040-8428(03)00172-0. View

Duits L, Ravensbergen B, Rademaker M, Hiemstra P, Nibbering P . Expression of beta-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells. Immunology. 2002; 106(4):517-25. PMC: 1782759. DOI: 10.1046/j.1365-2567.2002.01430.x. View

Alba R, Bosch A, Chillon M . Gutless adenovirus: last-generation adenovirus for gene therapy. Gene Ther. 2005; 12 Suppl 1:S18-27. DOI: 10.1038/sj.gt.3302612. View

10.

Reading P, Holmskov U, Anders E . Antiviral activity of bovine collectins against rotaviruses. J Gen Virol. 1998; 79 ( Pt 9):2255-63. DOI: 10.1099/0022-1317-79-9-2255. View

11.

Bastian A, Schafer H . Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept. 2001; 101(1-3):157-61. DOI: 10.1016/s0167-0115(01)00282-8. View

12.

Cerullo V, Seiler M, Mane V, Brunetti-Pierri N, Clarke C, Bertin T . Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther. 2007; 15(2):378-85. DOI: 10.1038/sj.mt.6300031. View

13.

Zhang Y, Chirmule N, Gao G, Qian R, Croyle M, Joshi B . Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther. 2001; 3(5 Pt 1):697-707. DOI: 10.1006/mthe.2001.0329. View

14.

Gropp R, Frye M, Wagner T, Bargon J . Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Hum Gene Ther. 1999; 10(6):957-64. DOI: 10.1089/10430349950018355. View

15.

Worgall S, Leopold P, Wolff G, Ferris B, Van Roijen N, Crystal R . Role of alveolar macrophages in rapid elimination of adenovirus vectors administered to the epithelial surface of the respiratory tract. Hum Gene Ther. 1997; 8(14):1675-84. DOI: 10.1089/hum.1997.8.14-1675. View

16.

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

17.

Krijgsveld J, Zaat S, Meeldijk J, van Veelen P, Fang G, Poolman B . Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem. 2000; 275(27):20374-81. DOI: 10.1074/jbc.275.27.20374. View

18.

Muruve D, Barnes M, Stillman I, Libermann T . Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther. 1999; 10(6):965-76. DOI: 10.1089/10430349950018364. View

19.

Walters R, Grunst T, Bergelson J, Finberg R, Welsh M, Zabner J . Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem. 1999; 274(15):10219-26. DOI: 10.1074/jbc.274.15.10219. View

20.

Seregin S, Aldhamen Y, Appledorn D, Hartman Z, Schuldt N, Scott J . Adenovirus capsid-display of the retro-oriented human complement inhibitor DAF reduces Ad vector-triggered immune responses in vitro and in vivo. Blood. 2010; 116(10):1669-77. PMC: 2947391. DOI: 10.1182/blood-2010-03-276949. View